These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 3422087)

  • 41. Peritoneal dialysis fluid (PDF) C++ and 1,25(OH)2D3 modulate peritoneal macrophage (PM0) antimicrobial activity in CAPD patients.
    Carozzi S; Nasini MG; Schelotto C; Caviglia PM; Barocci S; Cantaluppi A; Salit M
    Adv Perit Dial; 1990; 6():110-3. PubMed ID: 1982785
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Correlation of immunogenicity and production of ornithine by peritoneal macrophages.
    Kriegbaum H; Benninghoff B; Häcker-Shahin B; Dröge W
    J Immunol; 1987 Aug; 139(3):899-904. PubMed ID: 3110288
    [TBL] [Abstract][Full Text] [Related]  

  • 43. CD40 ligand expression on macrophages during peritonitis in continuous ambulatory peritoneal dialysis patients.
    Yang X; Ye RG; Kong QY; Yang QQ; Gao Y; Zhong JH; Wang T
    Adv Perit Dial; 2000; 16():213-5. PubMed ID: 11045296
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The effect of dwell time on peritoneal phagocytic defense of chronic peritoneal dialysis patients.
    Vlaanderen K; de Fijter CW; Bos HJ; van der Meulen J; Beelen RH; Oe PL; Verbrugh HA
    Adv Perit Dial; 1989; 5():151-3. PubMed ID: 2577399
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Fas expression on peritoneal macrophages during continuous ambulatory peritoneal dialysis peritonitis.
    Chen CY; Wu CY; Tsai TC; Lin WT; Lee WJ; Su CC; Chen HC; Chiang HC
    Ren Fail; 2008; 30(3):297-301. PubMed ID: 18350449
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Short dwell times reduce the local defence mechanism of chronic peritoneal dialysis patients.
    Vlaanderen K; Bos HJ; de Fijter CW; Oe LP; van der Meulen J; Verbrugh HA; Beelen RH
    Nephron; 1991; 57(1):29-35. PubMed ID: 2046812
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Potential use of tuftsin in treatment of candida peritonitis in a murine model.
    Levy R; Kain Z; Chaimovitz C; Fridkin M; Segal S; Alkan M
    J Biol Regul Homeost Agents; 1989; 3(2):71-8. PubMed ID: 2554684
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Role of mesothelial cells in peritoneal antibacterial defence.
    Muijsken MA; Heezius HJ; Verhoef J; Verbrugh HA
    J Clin Pathol; 1991 Jul; 44(7):600-4. PubMed ID: 1856294
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Ultrastructure of mononuclear phagocytes developing in liquid bone marrow cultures. A study on peroxidatic activity.
    van der Meer JW; Beelen RH; Fluitsma DM; van Furth R
    J Exp Med; 1979 Jan; 149(1):17-26. PubMed ID: 570211
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Peritoneal transport status influence on atherosclerosis/inflammation in CAPD patients.
    Sezer S; Tutal E; Arat Z; Akçay A; Celik H; Ozdemir FN; Haberal M
    J Ren Nutr; 2005 Oct; 15(4):427-34. PubMed ID: 16198934
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Specific characteristics of peritoneal leucocyte populations during sterile peritonitis associated with icodextrin CAPD fluids.
    Glorieux G; Lameire N; Van Biesen W; Dequidt C; Vanholder R
    Nephrol Dial Transplant; 2003 Aug; 18(8):1648-53. PubMed ID: 12897108
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Human peritoneal B-1 cells and the influence of continuous ambulatory peritoneal dialysis on peritoneal and peripheral blood mononuclear cell (PBMC) composition and immunoglobulin levels.
    Donze HH; Lue C; Julian BA; Kutteh WH; Kantele A; Mestecky J
    Clin Exp Immunol; 1997 Aug; 109(2):356-61. PubMed ID: 9276533
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparative study on peroxidatic activity in inflammatory cells on cutaneous and peritoneal implants.
    van der Rhee HJ; van der Burgh-de Winter CP; Tijssen JG; Daems WT
    Cell Tissue Res; 1979 Apr; 197(3):397-412. PubMed ID: 455406
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Biocompatibility of peritoneal dialysis fluids.
    Jörres A; Topley N; Gahl GM
    Int J Artif Organs; 1992 Feb; 15(2):79-83. PubMed ID: 1555880
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Intraperitoneal nitric oxide production in patients treated by continuous ambulatory peritonal dialysis.
    Davenport A; Fernando RL; Varghese Z
    Blood Purif; 2004; 22(2):216-23. PubMed ID: 15044821
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Enhanced expression of TGF-beta 1 by peritoneal macrophages in CAPD patients.
    Wang T; Ghen YG; Ye RG; Mai WY; Zhen ZH; Li HQ
    Adv Perit Dial; 1995; 11():11-4. PubMed ID: 8534680
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Complications of continuous ambulatory peritoneal dialysis: evaluation with CT.
    Cakir B; Kirbaş I; Cevik B; Ulu EM; Bayrak A; Coşkun M
    Diagn Interv Radiol; 2008 Dec; 14(4):212-20. PubMed ID: 19061167
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Calcification and osteopontin localization in the peritoneum of patients on long-term continuous ambulatory peritoneal dialysis therapy.
    Nakazato Y; Yamaji Y; Oshima N; Hayashi M; Saruta T
    Nephrol Dial Transplant; 2002 Jul; 17(7):1293-303. PubMed ID: 12105255
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Advanced glycation end products stimulate tumor necrosis factor-alpha and interleukin-1 beta secretion by peritoneal macrophages in patients on continuous ambulatory peritoneal dialysis.
    Rashid G; Korzets Z; Bernheim J
    Isr Med Assoc J; 2006 Jan; 8(1):36-9. PubMed ID: 16450750
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Increased plasma lipoprotein(a) in continuous ambulatory peritoneal dialysis is related to peritoneal transport of proteins and glucose.
    Heimbürger O; Stenvinkel P; Berglund L; Tranoeus A; Lindholm B
    Nephron; 1996; 72(2):135-44. PubMed ID: 8684516
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.